Gerard J. Criner, MD, FACP, FACCP, Director of the Temple Lung Center, participated in a video interview with HCPLive at the ATS International Conference on his research on pooled results from the METREX, METREO and MATINEE trials on mepolizumab, a humanized monoclonal antibody specifically targeting interleukin-5. This research showed that as an add-on treatment to inhaled triple therapy, mepolizumab significantly reduces the risk of exacerbations requiring hospitalization in a wide spectrum of patients with COPD, with BEC starting from 150 cells/µL, compared with placebo.
800-TEMPLE-MED
Request Appointment
SEARCH TEMPLE HEALTH